Compare TROO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROO | AGEN |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.1M | 274.8M |
| IPO Year | 2008 | 1999 |
| Metric | TROO | AGEN |
|---|---|---|
| Price | $2.15 | $6.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 367.3K | ★ 996.7K |
| Earning Date | 05-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.96 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.15 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $1.02 | $2.71 |
| 52 Week High | $5.28 | $8.85 |
| Indicator | TROO | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 44.89 |
| Support Level | $1.79 | $2.97 |
| Resistance Level | $2.27 | $8.70 |
| Average True Range (ATR) | 0.20 | 0.53 |
| MACD | 0.01 | -0.21 |
| Stochastic Oscillator | 51.61 | 12.37 |
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.